Articles

The addition of the lymphocyte activation gene-3 (LAG-3)-blocking antibody relatlimab to nivolumab (Opdivo) led to significantly longer progression-free survival (PFS) compared with nivolumab alone in previously untreated patients with advanced melanoma, according to results of the phase 3 RELATIVITY-047 clinical trial presented at the American Society of Clinical Oncology 2021 virtual annual meeting. Read More ›

The addition of the tyrosine kinase inhibitor tucatinib (Tukysa) to trastuzumab (Herceptin) and capecitabine continued to improve overall survival (OS) and progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer, according to updated results from the pivotal HER2CLIMB trial. Read More ›

The addition of ¹⁷⁷Lu-PSMA-617, a radionuclide therapy that targets prostate-specific membrane antigen (PSMA), to standard-of-care treatment resulted in a 38% reduction in the risk for death versus standard of care alone in men with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase 3 VISION clinical trial, which were presented during a plenary session at the American Society of Clinical Oncology (ASCO) 2021 virtual annual meeting. Read More ›

Approximately 13% of patients with lung adenocarcinoma harbor the KRAS p.G12C mutation, which is associated with poor clinical outcomes. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between June 30, 2021, and July 26, 2021. Read More ›

CDK4/6 inhibitors combined with anti-HER2 agents in HER2-low expressing MBC cases warrant prospective evaluations. Read More ›

Evidence from studies indicates that common genetic and epigenetic features of male and female breast cancer are not shared, but further studies are warranted. Read More ›

Breast cancer survivors should be closely monitored and offered appropriate evidence-based treatment for fatigue, cognitive dysfunction, and sexual problems. Read More ›

An analysis of racial minority groups treated for breast cancer demonstrates worse survival outcomes. Read More ›

Breast cancer’s initiation, progression, and behavior may be affected by chronic inflammation. Read More ›